Product Commercialization, Going Beyond Demand Generation

The pharmaceutical market has rapidly evolved and is now comprised of high-cost, complex specialty drugs, intended for specific rare and orphan disease as well as cell and gene therapies. Many of these new specialty drugs offer hope for previously untreatable conditions and greatly improve patient quality of life and in the case of cell and gene therapies, potential cures. However, the pharmaceutical landscape, and the requirements and knowledge needed to successfully commercialize these new specialty drugs, have grown increasingly complex and focus on narrow patient populations and indications.

In this informative whitepaper from Blue Fin Group, experts demystify patient funnel questions and consider the complexities of today’s market.

Download now!